Progressively disturbed visuoperceptual and visuospatial processing commonly manifests as visual field defects, visual agnosia, and environmental disorientation, with or without additional elements of Balint or Gerstmann syndromes. [1] [2] [3] [4] Visual deficits may appear in isolation, reflecting preferential involvement of posterior structures subserving visuoperceptual and visuospatial processing, or posteriorpredominant dysfunction may manifest as a component of a more generalized dementia syndrome. 1 Although clinicopathologic series establish AD pathology as the most common cause of PCA, 1, 2, 5 other pathologies are also associated with this syndrome. 1, 2, 6 Until recently, our ability to visualize the distribution of AD neuropathologic change during life was limited to the indirect measurement of b-amyloid burden using positron emission tomography (PET) ligands specific for the detection of fibrillary b-amyloid. 7, 8 Although some studies in patients with PCA report posterior-predominant b-amyloid deposition, 9-12 regional specificity is not consistently seen when comparing individuals with PCA to those with more typical amnestic AD dementia, [13] [14] [15] suggesting that b-amyloid imaging may predict the diagnosis of AD, but not the clinical phenotype. The recent advent of novel PET ligands has facilitated in vivo visualization of tau topographies in the brains of individuals with typical [16] [17] [18] and atypical AD presentations. 15, 19 Qualitative analyses of flortaucipir (tau) PET imaging in individuals with PCA have demonstrated posterior-predominant uptake compared with cognitively normal (CN) controls, 15 suggesting that tau deposition predicts neurodegeneration and neuronal dysfunction in PCA caused by AD. 20 However, it is unclear whether there are significant differences in flortaucipir binding in individuals with symptomatic PCA and amnestic AD dementia. We determined the density and distribution of flortaucipir binding in individuals with very mild PCA and amnestic AD dementia [Clinical Dementia Rating (CDR), 0.5] to examine whether binding patterns would differentiate individuals in the earliest clinically detectable stages of disease. We hypothesized that flortaucipir PET binding would distinguish patients with PCA and amnestic AD dementia, defining areas most vulnerable to tau deposition in PCA.
METHODS

Standard Protocol Approvals, Registrations, and Patient Consents
Consecutive patients with PCA (N = 5; CDR = 0.5) were recruited from the university-affiliated Memory Diagnostic Center outpatient clinic. Participants with amnestic AD dementia (CDR = 0.5) and CN controls (CDR = 0) were enrolled in longitudinal studies of memory and aging at the Knight Alzheimer Disease Research Center (ADRC). Twentytwo participants meeting criteria for amnestic AD dementia 21 and 47 CN controls completed florbetapir (b-amyloid) and/or flortaucipir PET; findings were compared with those observed in the 5 PCA individuals. Patients and participants consented to study participation, including review of clinical records, and structural and PET neuroimaging. Study protocols were approved by the Washington University School of Medicine Human Subjects Committee, and registered with ClincalTrials.gov (NCT02414282, NCT02414347).
Clinical Assessment and Eligibility Criteria
Longitudinal symptoms and signs, and results of neuropsychological testing and investigations were obtained from Memory Diagnostic Center records or the Knight ADRC research database. All individuals were evaluated by experienced clinicians using a semistructured interview with a knowledgeable collateral source and the symptomatic individual, and including a detailed neurological examination of the affected individual. A clinical diagnosis of dementia was considered at the conclusion of each assessment, integrating results from the clinical assessment and bedside measures of cognitive function (including the MiniMental Status Examination 22 ). Dementia was diagnosed according to National Institute on Aging-Alzheimer's Association diagnostic criteria, 21, 23 and staged using the global CDR. 24 The severity of cognitive impairment was indicated by the CDR Sum of Boxes. 25 PCA was diagnosed in individuals fulfilling Tang-Wai clinical diagnostic criteria. 2 Briefly, these criteria require the insidious onset and gradual progression of visual symptoms, together with objective demonstration of visuospatial/visuoperceptual deficits (eg, elements of Gerstmann or Balint syndrome, visual field defect, or prominent environmental disorientation) that result in substantial disability, and occur in the absence of primary ocular disease or an alternate cause of findings (eg, stroke, tumor). Individuals with parkinsonism and/or asymmetric sensory/motor signs consistent with corticobasal degeneration were excluded.
Control participants were deemed "cognitively normal" by Knight ADRC clinicians (CDR, 0). Recruitment of affected individuals was limited to those in the earliest symptomatic stage of disease (CDR, 0.5), encompassing individuals with mild cognitive impairment due to AD and very mild AD dementia. 21, 23, 26 The medical records of individuals diagnosed with PCA were reviewed for eligibility, and those meeting diagnostic criteria were invited to enroll. Participants were consecutively accrued from 2014 to 2016, representing all eligible participants with available florbetapir or flortaucipir imaging data. Eligible participants with only one available imaging modality were enrolled in the interest of maximizing analytic power. All participants were selected on the basis of clinical diagnosis and dementia staging, without prior knowledge of AD biomarker results (cerebrospinal fluid or PET imaging measures of an AD pathophysiologic process). Thus, it is possible that affected cohorts could include individuals with non-AD pathology, or that individuals with preclinical AD could be included as CN controls. The emphasis on assignment based on clinical presentation was selected to reflect clinical practice, where AD biomarkers are seldom known a priori.
Neuroimaging
T 1 -weighted magnetic resonance images were acquired using a Magnetization Prepared Rapid Acquisition Gradient Echo sequence with repetition time (TR) = 2300 ms, echo time (TE) = 2.95 ms, flip angle (FA) = 9 degrees, 176 slices, in plane resolution 240Â256, slice thickness = 1.2 mm acquired in sagittal orientation. Images underwent volumetric segmentation using FreeSurfer 5.3 (http://freesurfer.net) to identify a cerebellar region of interest used in the PET analyses.
All individuals with PCA, 20/22 (91%) of amnestic AD participants, and 42/47 (89%) of CN controls underwent b-amyloid PET imaging using florbetapir ( 18 F-AV-45). Individuals received a bolus injection of between 7.7 and 11.5 mCi of florbetapir, and data from the 50-to 70-minute postinjection window were converted to standardized uptake value ratios (SUVRs), relative to cerebellar gray matter. All PCA patients, 11/22 (50%) amnestic AD participants, and all CN controls underwent tau-PET imaging using flortaucipir ( 18 F-AV-1451). Individuals received a bolus injection of between 7.2 and 10.9 mCi of flortaucipir. Data from the 80-to 100-minute postinjection window were converted to SUVRs using the whole cerebellum as a reference, in accordance with established techniques. 16, 17 For descriptive purposes PET data was analyzed using a region of interest approach. Summary measures of florbetapir 27 and flortaucipir (S. Mishra et al, unpublished data) are presented in Table 1 .
Statistical Analyses
Clinical data were analyzed using SPSS Statistics (IBM Corp., Version 24.0. Armonk, NY). Comparisons across all 3 cohorts (PCA, amnestic AD, CN controls) were performed using the nonparametric Kruskal-Wallis test. Continuous and categorical measures were compared using the Mann-Whitney U test, and the Fisher exact test, respectively. Statistical significance was defined as P < 0.05, unless otherwise defined.
PET neuroimaging data were filtered with an 8 mm Gaussian kernel and placed into a common anatomic space before analysis using a linear registration. Voxelwise PET data were analyzed using nonparametric permutation testing implemented using Randomize, 28 part of the fMRI Brain Software Library suite (http://fsl.fmrib.ox.ac.uk).
Permutation techniques provide exact control of false positive rates and provide a more robust approach to analyzing PET or structural magnetic resonance imaging data. 29, 30 The identification of significant clusters was performed using threshold-free cluster enhancement, 31 also implemented using the FSL suite. Significance maps were corrected for multiple comparisons using a family-wise error rate of P < 0.05. Statistical models included age as a covariate. Table 1 details demographic and clinical features for individuals with PCA, amnestic AD dementia, and CN controls. Individuals with PCA differed from those with amnestic AD dementia, with younger age at symptom onset (P = 0.001), and with visuospatial/perceptual symptoms at presentation (P < 0.001). There was a trend toward a greater proportion of females in the PCA group (P = 0.06). Visuoperceptual abnormalities (P < 0.001), alexia (P = 0.003), and apraxia (P < 0.001) reliably distinguished PCA patients from participants with amnestic AD dementia. Although individuals with PCA did not initially present with memory complaints, memory impairment developed in all PCA individuals by the clinical assessment nearest flortaucipir PET imaging. No differences were observed in dementia severity, as measured using the CDR Sum of Boxes (P = 0.52), performance on the Mini-Mental State Examination (P = 0.25), or duration of wSignificantly different from participants with amnestic AD dementia. zSignificantly different from patients with PCA; significance defined as P < 0.017 (P < 0.05, Bonferroni corrected for multiple comparisons). *Mini-Mental State Examination data available from 4 patients with PCA; 1 patient was unable to complete testing due to the severity of visuoperceptual/ spatial deficits.
RESULTS
AD indicates Alzheimer disease; CDR, Clinical Dementia Rating; CDR-SB, Clinical Dementia Rating-Sum of Boxes; CN, cognitively normal; PCA, posterior cortical atrophy; SUVR, standardized uptake value ratios. symptomatic illness (P = 0.62) at the time of flortaucipir PET imaging.
Mean florebetapir and flortaucipir deposition for individuals with PCA, amnestic AD dementia, and CN controls are depicted in Figure 1 . Mean b-amyloid SUVRs exceeded predefined thresholds for the diagnosis of a "positive" scan (mean SUVRZ1.27 = consistent with AD 17 ) in all patients with PCA and in 17/20 imaged participants with amnestic AD dementia. Significance maps comparing tracer uptake between groups are presented in Figure 2 (uptake within the right hemisphere is shown for ease of presentation; bilateral hemispheric data are presented in supplementary materials: eFigures 1-4, Supplemental Digital Content 1, http://links.lww.com/ WAD/A164). No laterality effects were noted. Florbetapir uptake distinguished individuals with early-stage symptomatic PCA and amnestic AD dementia from CN controls (Figs. 2A,  B, left) . Both symptomatic groups demonstrated elevated levels of b-amyloid in stereotypical AD regions, including the precuneus, posterior cingulate, temporal lobe, medial prefrontal cortex, and the bilateral parietal lobes. Unique to PCA patients, flortaucipir uptake was also increased in posterior areas (visual cortex), relative to controls. At the whole-brain level there were no significant differences in florbetapir uptake in the PCA and amnestic AD dementia groups. However, when comparisons were limited to voxels with significant increases in flortaucipir binding, significantly greater florbetapir uptake was noted in the visual cortices of individuals with PCA (Fig. 2C, left) .
Relative to CN controls, flortaucipir uptake in individuals with PCA and amnestic AD dementia was significantly elevated throughout the temporal lobe, temporal parietal junction, precuneus, posterior cingulate, lateral parietal regions, lateral occipital cortex, and prefrontal cortex (Figs. 2A, B, right) . When compared with individuals with amnestic AD dementia, flortaucipir uptake was consistently elevated within the primary and secondary visual areas, as well as bilateral parietal and supplementary motor cortices of individuals with PCA (Fig. 2C, right) . The topographical distribution of tau-PET binding was unchanged when controlling for mean cortical levels of b-amyloid PET deposition (eFigure 5, Supplemental Digital Content 1, http://links.lww.com/WAD/A164). In addition, flortaucipir uptake in individuals with PCA was consistently demonstrated at or above levels observed in individuals with amnestic AD dementia within regions previously shown to reflect tau topographies relevant to amnestic AD 16 (Fig. 3) , after controlling for age and mean cortical levels of b-amyloid PET deposition ( Table 2) .
DISCUSSION
Tau-PET (flortaucipir) uptake within posterior brain regions, particularly the primary and secondary visual areas, distinguished individuals with early-stage symptomatic PCA and amnestic AD dementia. These findings build upon initial reports establishing preferential tau-PET binding in the posterior cortical regions of small cohorts of patients with PCA versus CN controls, 15 defining cardinal areas of increased tau deposition specific to patients with very mild dementia due to PCA. In addition, increased florbetapir binding was seen within posterior cortical regions that also demonstrated the greatest flortaucipir uptake, extending findings from other in vivo studies approximating b-amyloid deposition in individuals with PCA. [9] [10] [11] [12] The ability to differentiate individuals with varying phenotypes of AD using in vivo b-amyloid-and tau-PET imaging in this study, but not others, [13] [14] [15] may reflect inclusion criteria emphasizing recruitment of individuals with the earliest manifestations of symptomatic AD. Together, these findings suggest that posterior regions remain uniquely vulnerable to AD pathology, with tau deposition detectable early in the symptomatic course. By extension, preferential tau deposition within posterior regions may underlie the emergence of visuospatial/perceptual symptoms and signs that define the early stages of PCA due to AD.
Although flortaucipir uptake within posterior regions distinguished individuals with early symptomatic PCA from those with amnestic AD dementia in our series, it is important to note that tau deposition was not limited to these areas. On the contrary, comparable levels of flortaucipir binding were observed in individuals with PCA within brain areas commonly affected in amnestic AD. These findings suggest that the fundamental topographical distribution of tau pathology overlaps substantially in individuals with AD. Similar findings were observed when comparing regional b-amyloid topography: differences in florbetapir uptake were revealed only following post hoc comparisons involving regions most susceptible to tau deposition. The intersection of neuropathology likely explains the overlapping patterns of cortical atrophy previously reported within the bilateral parietal, occipital, precuneus, posterior cingulate, posterior temporal and hippocampal regions of individuals with visual and amnestic AD. 32 Together, these findings support a common process governing the progression of AD neuropathologic change. It fits, therefore, that patient-specific factors may convey vulnerability to regional AD pathology, and by extension, disease phenotype. This suggestion is supported by the earlier age at symptom onset reported in individuals with PCA in this study and others, 33, 34 by a potential sex bias (with a higher proportion of female patients diagnosed with PCA), 2, 13, 32, [35] [36] [37] and by emerging reports identifying putative genetic associations in individuals with PCA. 2, 38, 39 Findings from this small cohort of individuals with symptomatic AD dementia add to the limited literature considering in vivo imaging of AD neuropathologic change, FIGURE 2. Significant elevations in b-amyloid and tau pathology between groups. Maps depicting significant elevations in b-amyloid (left) and tau-PET deposition in individuals with amnestic Alzheimer disease (AD) dementia relative to cognitively normal controls (A); posterior cortical atrophy (PCA) relative to cognitively normal controls (B); and PCA relative to amnestic AD dementia (C). The significant elevations in b-amyloid in individuals with PCA relative to those with amnestic AD dementia were only significant when restricting analyses to those voxels that showed significantly greater tau deposition. All comparisons control for differences in age. suggesting that regional differences in the deposition of both b-amyloid and tau predict posterior-predominant dysfunction in PCA. Differences between regional b-amyloid deposition between this study and others, [13] [14] [15] may reflect differences in study populations (this study favored recruitment of individuals with early-stage symptomatic AD), methodological differences owing to variations in PET-tracers (b-amyloid imaging was performed in other studies using [ 11 C] Pittsburgh compound B), or differences in the comparison populations. Although PCA and amnestic AD dementia cohorts were matched for dementia severity (emphasizing inclusion of individuals with very mild dementia, global CDR 0.5), CDR has been primarily validated in populations with amnestic AD. Thus, it remains possible that this measure may underestimate disease severity in patients with atypical (ie, visual) AD presentations. However, disparity in dementia severity is unlikely to fully account for differences in b-amyloid and tau deposition observed in PCA patients, as regional differences in tau deposition persisted even after controlling for mean cortical levels of florbetapir (b-amyloid) PET uptake (eFigure 5)-a proxy imaging measure of disease severity. Finally, the possibility that b-amyloid and tau deposition (or tracer uptake) are fundamentally different in younger individuals cannot be excluded. 15 Although statistical models controlled for age, such a finding could yet contribute to observed differences in flortaucipir uptake.
Our findings suggest that early tau deposition within primary and secondary visual areas corresponds to the emergence of visuoperceptual and visuospatial compromise in patients with PCA. Extending this logic, the gradual spread of tau pathology to signature AD regions (eg, the precuneus, medial temporal lobes, and frontal lobes) should predict the emergence of typical symptoms and signs of AD dementia. Tau deposition and propagation may be preceded by regionalspecific b-amyloid deposition; alternatively, tau deposition may occur independent of this process. These hypotheses may be further evaluated through longitudinal PET imaging studies in greater numbers of PCA patients, with the potential to better understand both the mechanisms that give rise to the posterior-anterior gradient of neurofibrillary tangle pathology reported at the nadir of disease, 2, 6 and the factors that convey regional vulnerability to AD neuropathologic change.
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